HomeNewsBusinessAmid startup boom, second COVID-19 wave plays spoilsport

Amid startup boom, second COVID-19 wave plays spoilsport

The second wave of the coronavirus pandemic is hitting startups, with many companies having dozens test positive in a few days. Founders are prioritizing employee care, even as startups have parallelly been on a funding tear and investors have been more aggressive then ever before.

Mumbai / April 23, 2021 / 08:16 IST
Story continues below Advertisement
Until last month, many startups had teams such as sales and marketing work from the office or warehouses, while product and tech teams worked from home in the last few months, but companies are now telling all employees to stay home home once again. (Image: Shutterstock)
Until last month, many startups had teams such as sales and marketing work from the office or warehouses, while product and tech teams worked from home in the last few months, but companies are now telling all employees to stay home home once again. (Image: Shutterstock)

Indian startups have been on an unprecedented tear, growing and raising money like never before, even prompting questions about a valuation bubble, but the second wave of the coronavirus infections now threatens to derail some of that momentum.

A number of startups in Mumbai, Bengaluru, Hyderabad and Delhi have seen dozens of employees test positive for the virus, and in many cases, key leaders and even founders have been down with the virus. In some of these cases, employees in offline-heavy sectors such as e-commerce and lending have contracted the virus while on duty, and are now scrambling for oxygen cylinders, remdesivir and hospital beds.

Story continues below Advertisement

For example, Akshay Chaturvedi, founder and CEO of education firm Leverage Edu, spent most of the last couple of days helping out his team members, running from pillar to post to secure beds and oxygen in New Delhi, although his business - of sending students abroad for higher education, is actually peaking as infections fall and vaccinations rise in the United States and Canada.

Follow our LIVE Updates on the coronavirus pandemic here

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show